ClinicalTrials.gg
CompletedNCT07181538Updated Sep 18, 2025

Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers

A Phase 1 interventional study of JLP-2302 and JP-1366 in Healthy, sponsored by Onconic Therapeutics Inc.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Feb 2025, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This study aims to evaluate the pharmacokinetics and the safety after administration of "JLP-2302" and "JP-1366" in healthy volunteers.

02

Conditions studied

  • Healthy

Keywords

  • pharmacokinetic
03

In context

Lead sponsor

Onconic Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a (BMI) between 18.0 and 30.0 kg/m²
  • Subjects without any congenital or chronic disease, and with no pathological findings based on medical examination
  • Subjects who agree to use a medically acceptable method of *

Exclusion criteria

Exclusion Criteria:

  • Subjects who have taken enzyme-inducing or -inhibiting drugs
  • Subjects who have participated in a bioequivalence or other clinical trial and received an product within 6 months prior to the first dose
  • Subjects with a history of gastrointestinal surgery that may affect drug absorption
  • Subjects with a history of psychiatric illness
  • Female subjects who are pregnant, suspected of being pregnant, or currently breastfeeding
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    JLP-2302 and JP-1366 crossover

    Drug: JLP-2302 · Drug: JP-1366

  • Active comparator
    JP-1366 and JLP-2302 crossover

    Drug: JLP-2302 · Drug: JP-1366

Interventions

  • DrugJLP-2302

    taking JLP-2302

  • taking JP-1366

06

What researchers measure

Primary outcomes

  1. Area under the plasma drug concentration-time curve(AUCt)

    Time frame: Pre-dose on Day 1 and on Days 2 post-dose

  2. Peak Plasma Concentration (Cmax)

    Time frame: Pre-dose on Day 1 and on Days 2 post-dose

07

Study locations

1 site
  • Yangji Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Feb 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Sep 18, 2025
StartActual
Feb 4, 2025
Primary completionActual
Feb 20, 2025
CompletionActual
Mar 5, 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07181538
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Feb 4, 2025
Primary completion
Feb 20, 2025
Completion
Mar 5, 2025
Last update
Sep 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zastaprazan

Start the discussion